1.
OvCa cells are unique among cancers that they have diverse progenitors that express common epithelial markers as keratins, EpCAM and E-cadherin as well as mesenchymal markers as vimentin and N-cadherin. 7 Malignant cells are shed from the primary tumor into the peritoneal cavity survive as free-floating single cells or spheroids in the "malignant ascitic fluid" that is encountered in the majority of patients with OvCa. 6, 8 Single cells and spheroids can survive anchorage-independent apoptosis "anoikis," proliferate in suspension and seed onto the mesothelial lining of the peritoneal cavity, resulting in extensive peritoneal dissemination. 9 Malignant cells isolated from ascitic fluid exhibit dual "hybrid" as well as heterogeneous E-and N-Cadherin expression. 9 This cadherin-plasticity influences cell-cell interactions, spheroid formation, and is implicated in the dynamic switch between epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET). EMT-MET switch is regulated by sequential transcriptional machinery with early induction of the transcription factors SNAIL (SNAI1); followed by SNAI2 (SLUG), ZEB1/2 and TWIST. [10] [11] [12] [13] EMT-transcription factors are induced by a plethora of upstream factors that act individually or synergistically to induce an OvCa invasive phenotype. In addition to intrinsic EMT inducers activated in cancer cells, cues from the peritoneal TME strongly induce EMT. [14] [15] [16] [17] The expression of EMT-inducing transcription factors is associated with metastatic, recurrent, and chemo-resistant tumors. 3, 10, 18 The correlation between EMT and aggressiveness of OvCa is supported by E-cadherin downregulation 19 and overexpression of mesenchymal signatures specifically transforming growth factor-beta and its receptors (TGFβ/TGFβRs), CD44, 20 bone morphogenetic proteins and their receptors (BMPs/BMPRs), receptor tyrosine kinases and their ligands, 13 Wnt 21, 22 and Notch 12 signaling pathways. 
Mesothelial cells

3.
The omentum is a double-layered peritoneal fold that covers the intestines and abdominal organs. Physiologically, it functions as a fat and energy depot due to the abundance of white adipocyte. 40, 41 The bidirectional interaction between omental adipocytes and cancer cells is instigated by cancer cell secretome inducing dedifferentiation and reprogramming of adipocytes into a pre-adipocyte/fibroblastoid stage secreting adipokines, 42, 43 cancer-associated adipocytes (CAA) 43 ( Figure 1 ). In this process, lipolysis is induced in adipocytes releasing fatty acids and glycerol. In turn, OvCa cells take up and use fatty acids for generation of energy by β-oxidation 42 to meet the increasing demands of the rapidly proliferating cells.
Cancer-associated fibroblasts (CAFs). The origin of
CAFs in the peritoneal milieu is still enigmatic. Many studies highlighted the significance and the roles of CAFs in OvCa peritoneal spread, 44, 45 response to standard of care therapy, and even proposed the importance of targeting CAF-derived factors that support OvCa. [44] [45] [46] [47] [48] In the peritoneal milieu, CAFs stem from various origins. The activation of resident fibroblasts and mesenchymal stem cells has been considered the main origin of CAFs. 49 Mesothelial cells present an important source of activated fibroblasts in inflammatory/fibrotic pathologies as peritoneal dialysis, where they are converted into myofibroblasts through mesothelial to mesenchymal transition (MMT). 50 In support of this, submesothelial fibroblasts expressed both mesothelial (calretinin, cytokeratins, mesothelin) and myofibroblast (α-SMA) markers in specimens from patients with peritoneal metastases from ovarian and colon cancers. 51 Another source of CAFs is omental adipocytes that have undergone delipidation/dedifferentiation. 43, 52, 53 This hypothesis was based on reports of adipocyte de-differentiation into fibroblasts that occur in inflammatory fibrotic changes encountered in dysfunctional adipose tissues in obesity and type-2 diabetes. 54 Moreover, the endothelial to mesenchymal transition reported in vasculopathies and atherosclerotic plaques 55 was suggested as a source of CAFs in OvCa. 56 The CAF phenotype is induced by TME cues characterized by inflammation, and hypoxia, activating fibroblasts to exhibit characteristics of both myofibroblasts and secretory phenotype. [44] [45] [46] 51 OvCa cell motility and invasiveness by activating the NF-κB signaling pathway and by upregulating expression of CD44, matrix metalloproteinase-9, and the hyaluronanmediated motility receptor. 45 Other secreted ECM proteins upregulated and secreted by CAFs include periostin, 45, 57 secreted phosphoprotein, 57, 58 and cartilage oligomeric matrix protein (COMP). 45 These secreted ECM proteins, in turn, trigger a plethora of signaling pathways as PI3K-AKT as well as NFkB that promote OvCa spread, recurrence and chemoresistance. 45, 59, 60 In addition, increased number of CAFs was associated with advanced OvCa stage, higher frequency of metastases, and lymphatic and microvessel density. 48 The findings that the molecular cross-talk between cancer cells and CAFs in the OvCa TME is regulated by TGFβ/TGFβRs/SMAD pathway in CAFs and triggers multiple oncogenic pathways in OvCa cells warranted the initiation of clinical trials targeting TGFβ/TGFβRs as well as PI3K inhibitors in combination with standard of care therapy (summarized in Table 1 ).
5.
Tumor-associated macrophages (TAMs) are encountered in the pro-inflammatory peritoneal TME rich in cytokines/ chemokines that recruit macrophages. The cross-talk between cancer cells and TAMs upregulates the secretion of inflammatory mediators 27, 28, 61, 62 which influence tumor migration and invasion through activation of NFκB, the key regulator of pro-inflammatory molecules in TAMs and cancer cells. Increased TAMs not only promotes cancer cell invasiveness but also contributes to immunosuppressive environment suppressing T cells, dendritic (DCs) and natural killer (NK) cells functions. 8 TAMs also contribute to the phenotypic switch of fibroblasts into CAFs, and in turn activate multiple pathways that lead to chemoresistance, recurrence, and poor prognosis. 63, 64 The augmented inflammatory TME promoted clinical trials targeting inflammatory cytokines/chemokines and their receptors, as well as COX-2 inhibitors ( Treg subsets with upregulated CTLA-4 and downregulated expression of CD28. 84, 85 In vitro induced CD8 Tregs blocked CD4 T-cells proliferation via TGFβ1 and IFN-ɣ that not only increase the number of Tregs in peripheral blood of OvCa patients, but also recruit and stimulate Treg tumor infiltration and localization. 86 Natural killer cells (NK) are lymphocytes of the innate immune system that target cells with low MHC Class-I expression including tumor cells through cascades involving perforins/granzymes as well as Fas/FasL. 86 Tumor cells evade immune-surveillance via several mechanisms. For instance, MUC16/CA125, a high-molecular weight mucin overexpressed by OvCa has the ability to inhibit NK cell and downregulating CD16. Blocking ADAM17 maintains CD16 on the cell surface, enhancing CD16-mediated NK cell killing ability. 87 
9.
Endothelial cells are critical to maintain blood vessel structure, angiogenesis and vascular permeability. 88 Vascular endothelial growth factor (VEGF) has been
long identified as the key regulator of angiogenesis and vascular permeability and is produced by cancer and stromal cells. 89 VEGF contributes to the development of peritoneal carcinomatosis with malignant ascites. 90 Preclinical and clinical studies showed that VEGF levels inversely correlate with disease prognosis and patients' survival. 89, 91 VEGF inhibition suppresses tumor growth, dissemination, and ascites production. These findings promoted clinical evaluation and approval of agents targeting VEGF/VEGFRs in patients with OvCa as single agents or in combination with standard of care therapy. Deregulation of normal endothelium in the peritoneal TME is also induced by proangiogenic and pro-inflammatory factors, bioactive lipids and neuroendocrine hormones produced by OvCa and stromal cells in the peritoneal TME. 89, 91 This upregulation of the proangiogenic factors and their interconnected signaling pathways not only contributes to increased vascular permeability, tumor growth, and angiogenesis, but also contributes to the suboptimal response to standard of care therapy. 89, 91 Therefore, clinical trials targeting these proangiogenic factors, and their receptors in OvCa patients are currently underway (Table 1 ).
10.
Ascitic fluid develops due to increased vascular and mesothelial permeability with transudation of highprotein fluid from intravascular compartment to peritoneal cavity in OvCa patients. The oncogenic signals generated from growing tumors, concentrate in ascites, and dynamically change according to the disease subtype, stage, and grade, as well as among patients. The heterogeneity in ascites constituents and their relative concentrations is exemplified by the presence of both oncogenic and tumor suppressive factors. In HGSC, ascites promotes tumor invasiveness and survival and inhibits apoptosis leading to chemoresistance. 92 Along with the high protein concentration, increased inflammatory cytokines and chemokines and reduced lymphatic flow also contribute to the buildup of ascitic fluid and maintenance of an immunosuppressive TME that impairs the functions of innate and adaptive immune responses. 89, 93, 94 Ascites is rich in bioactive lipids as lysophosphatidic acid (LPA), that has been long identified as an OvCa promoting factor. 95 LPA is produced by
OvCa cells, as well as the other cellular components in the peritoneal TME. High levels of LPA in ascitic fluid lead to aberrant receptor signaling with activation of pro-inflammatory and pro-survival pathways as well as transactivation of receptor tyrosine kinases, that in turn, contribute to increased production of LPA, growth factors, cytokines/chemokines, 96, 97 further OvCa progression, and are associated with poor prognosis. Ascitic fluid contains secreted factors produced by the various cells in the peritoneal TME, yet, its utility for diagnosis and/or patient stratification for therapy is still limited. Factors enriched in the malignant ascitic fluid as VEGF, IL-6, IL-8, MMPs, and LPA, lack sensitivity, and specificity in OvCa. Combined detection of tumor markers in serum and ascites may improve their diagnostic/prognostic value. However, since ascitic fluid contains floating tumor and immune cells, it can serve as a reliable source for isolation of these cells for autologous immunotherapy. In addition, ascites-derived cancer cells could be used for generation of patient-derived xenografts for further characterization and therapeutic screening.
| TREATMENT
Initial treatment options are primary debulking surgery followed by chemotherapy or neoadjuvant chemotherapy followed by surgery. Standard chemotherapy involves carboplatin and paclitaxel. Various targeted therapies are being studied in combination with carboplatin/paclitaxel (Table 1 ). In addition to the FDA approved targeted therapies as poly (ADP-ribose) polymerase PARP inhibitors and VEGF inhibitors, other targeted therapies currently in clinical trials include inhibitors of angiogenesis (VEGF/VEGFRs, FGFRs, PDGFRα/β), multi-target receptor tyrosine kinase (RTKi), Cox-2, and cytokines and their receptors.
Recently, immunotherapy for advanced OvCa was introduced in clinical trials using immune checkpoint inhibitors targeting PD1, PDL1, and CTL4 to restore the ability of CTLs to eradicate tumor cells. Personalized therapy with autologous tumor and immune cells reprogrammed ex-vivo to stimulate the immune system and overcome immune evasion of OvCa cells are in clinical trials. Moreover, targeting tumor metabolism has recently gained more appreciation evidenced by clinical trials of metformin in advanced HGSC either alone or in combination of standard of care therapy (Table 1) .
| CONCLUSION
OvCa carries the largest burden of disease mortality among gynecologic malignancies. Despite initial response to firstline therapy, recurrence occurs within 18 months. Indeed, successful treatment of OvCa can be achieved by improving our understanding of the complex interplay of cancer cells within the unique peritoneal TME. Several lines of targeted drugs have improved progression-free survival in some patients with OvCa. For example, patients with ascites would benefit from VEGF targeted therapy. Patients with high intratumoral CD8 + TILs or increased CD8 + TILs in the ascitic fluid would benefit from immunotherapy or tumor vaccines. In addition, patients with amplified PI3K or harboring activating mutation of PIK3ca would benefit from PI3K inhibitors recently introduced in clinical trials (Table 1) . Moreover, the growing appreciation of therapeutic efficacy of metformin in OvCa patients, highlight the importance of targeting metabolic programming in OvCa. The strategies outlined in this review as well as the ongoing clinical trials are promising for improving the efficacy of TME-targeted therapeutics to improve disease outcome and patient quality of life.
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